Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 30 of 30
Family-Centered Behavioral Preparation for Surgery
NCT00261261
Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis
NCT00588874
Disulfiram for Cocaine Abuse in Buprenorphine Treatment
NCT00913484
Framing Messages for Smoking Cessation With Bupropion - 6
NCT00104598
Detection of Ischemia in Asymptomatic Diabetics
NCT00769275
Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1
NCT00023283
Cognitive Training and Enhanced Supported Employment in Schizophrenia
NCT00339170
Repetitive Transcranial Magnetic Stimulation for "Voices"
NCT00004980
Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children
NCT01967849
Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants
NCT00252681
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004923
Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00004924
Relational Parenting Group for Opioid-addicted Mothers
NCT00319241
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects
NCT00635102
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
NCT00003111
High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
NCT00002948
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
NCT00002947
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
NCT00002950
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2
NCT00000319
Naltrexone Treatment for Alcoholic Women
NCT00000448
Aminocamptothecin in Treating Patients With T-cell Lymphoma
NCT00002635
Combining Behavioral Treatment With Agonist Maintenance - 1
NCT00000311
Behavioral Treatment for Cocaine Dependent Women
NCT00914381
Disulfiram for Cocaine-Alcohol Abuse - 3
NCT00000278
Pemoline for Cocaine Abuse - 7
NCT00000282
Novel Medications for Opiate Detoxification - 4
NCT00000279
Pharmacotherapy for Schizophrenic Drug Users - 6
NCT00000281
Mazindol for Cocaine Abuse - 2
NCT00000277
Glutaminergic Agents for Cocaine Abuse - 5
NCT00000280
Dopamine Reuptake Inhibitors of Cocaine Abuse - 1
NCT00000276
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
NCT00002679
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
NCT00002680
Rapid Benzodiazepine Detoxification Using Flumazenil - 1
NCT00000246
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
NCT00002507
Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial
NCT00033917
Buprenorphine Maintenance for Opioid Addicts - 3
NCT00000204
Buprenorphine Maintenance for Opioid Addicts - 1
NCT00000202
Buprenorphine Maintenance for Opioid Addicts - 2
NCT00000203
Levetiracetam Treatment of Tardive Dyskinesia
NCT00291213
Smoking Cessation in Alcoholism Treatment
NCT00000454
Acamprosate Treatment: Mechanisms of Action
NCT00004552
Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1
NCT00000216
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.